Johnson & Johnson (JNJ) 123.90 $JNJ
Pharma ETFs Soaring on Solid Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 11:22AM CDT
Pharma ETFs are in focus in the days ahead on impressive Q2 results.
IHE: 156.52 (+0.77), BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), PPH: 61.96 (+0.06), PJP: 68.56 (+0.47), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), XPH: 46.68 (+0.54), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Maggie FitzPatrick Joins Exelon as Senior Vice President, Corporate Affairs
BusinessWire - Wed Aug 03, 10:13AM CDT
Exelon today announced it has appointed Maggie FitzPatrick as senior vice president of Corporate Affairs, Philanthropy and Customer Engagement, effective Aug. 29, 2016.
JNJ: 123.90 (-0.95), EXC: 36.57 (-0.21)
Global Pharmaceuticals Market Analytics Report 2016 Featuring Pfizer, Roche, Merk & Co., Sanofi, Gilead Sciences, Johnson & Johnson, Novartis, Abbvie, Amgen, GSK - Research and Markets
BusinessWire - Wed Aug 03, 8:13AM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Global Market Analytics Report 2016" report to their offering.
JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVS: 82.40 (-0.56)
Philogen Announces Collaboration With Johnson & Johnson Innovation
PR Newswire - Wed Aug 03, 7:00AM CDT
Philogen S.p.A. (a privately owned company) today announced that they have entered into a collaboration, option and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics. The agreement was facilitated by Johnson & Johnson Innovation.
JNJ: 123.90 (-0.95)
Medical benefits of dental floss unproven
By JEFF DONN - AP - Tue Aug 02, 1:13PM CDT
HOLMDEL, N.J. (AP) — It's one of the most universal recommendations in all of public health: Floss daily to prevent gum disease and cavities.
JNJ: 123.90 (-0.95)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.21 (+1.49), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), GERN: 2.78 (+0.06), CNAT: 2.37 (+0.04), AERI: 18.03 (+0.69), EXEL: 9.39 (+0.24)
Pfizer (PFE) Tops on Q2 Earnings, Revenues, Maintains View
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 8:08AM CDT
Pfizer (PFE) surpassed earnings and revenue estimates again in the second quarter.
JNJ: 123.90 (-0.95), PFE: 35.29 (-1.10), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Dermatological Drugs Market Forecast 2016-2026
PR Newswire Europe - Tue Aug 02, 8:03AM CDT
LONDON, August 2, 2016 /PRNewswire/ --
JNJ: 123.90 (-0.95)
Uptrend Call Working As Johnson & Johnson Stock Rises 22.4% (JNJ)
Comtex SmarTrend(R) - Tue Aug 02, 1:28AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on January 28th, 2016 at $102.45. In approximately 6 months, Johnson & Johnson has returned 22.41% as of today's recent price of $125.40.
JNJ: 123.90 (-0.95)
Stock Market News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Benchmarks closed mixed on Friday as upbeat tech earnings offset negative reports of energy firms and discouraging GDP data
KO: 43.64 (+0.11), AMZN: 754.64 (-5.94), FB: 122.51 (-0.58), LLTC: 59.22 (+0.05), XOM: 87.49 (+0.45), MS: 28.42 (+0.42), JNJ: 123.90 (-0.95), AA: 10.41 (+0.09), GS: 158.34 (+2.28), JPM: 64.66 (+1.01), MCD: 117.52 (-0.18), GOOGL: 798.92 (-1.20), MSFT: 56.97 (+0.39), CVX: 100.61 (+1.02), AAPL: 105.79 (+1.31)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)
Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:38AM CDT
With Geron (GERN) being a development stage company, investor focus will remain on imetelstat.
FATE: 2.06 (+0.01), JNJ: 123.90 (-0.95), GERN: 2.78 (+0.06), EXEL: 9.39 (+0.24)
Women with Ovarian Cancer from Baby Powder, Helped by Life Care Solution Group's Collaborative Effort
PR Newswire - Fri Jul 29, 11:46AM CDT
Greg Vigna, MD, JD, founder of Life Care Solutions Group and Jane Akre, founder of Mesh Medical Device News Desk today launch a collaborative effort to educate, empower, and assist catastrophically injured women with ovarian cancer, who were exposed to Johnson & Johnson Baby Powder containing Talc.
JNJ: 123.90 (-0.95)
AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 123.90 (-0.95), ABBV: 66.57 (-0.21), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Merck (MRK) Updates Outlook Following Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
Merck (MRK) surpassed Q2 earnings expectations by a penny while revenues were in-line with estimates.
JNJ: 123.90 (-0.95), MRK: 57.65 (-0.68), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVLS: 4.83 (+0.02), CYTR: 0.61 (+0.04), CEMP: 22.20 (+2.04), ACUR: 1.88 (+0.04), NVS: 82.40 (-0.56)
McKesson (MCK) Beats on Q1 Earnings, Maintains Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:11AM CDT
McKesson Corporation (MCK) reported first-quarter fiscal 2017 (ended Jun 30, 2016) earnings of $3.50 per share, above the Zacks Consensus Estimate of $3.35.
ABC: 89.89 (+0.46), JNJ: 123.90 (-0.95), MCK: 195.14 (+1.61), BMY: 74.80 (-0.25)
2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21)
Pharma ETFs Soaring on Solid Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 11:22AM CDT
Pharma ETFs are in focus in the days ahead on impressive Q2 results.
IHE: 156.52 (+0.77), BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), PPH: 61.96 (+0.06), PJP: 68.56 (+0.47), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), XPH: 46.68 (+0.54), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Maggie FitzPatrick Joins Exelon as Senior Vice President, Corporate Affairs
BusinessWire - Wed Aug 03, 10:13AM CDT
Exelon today announced it has appointed Maggie FitzPatrick as senior vice president of Corporate Affairs, Philanthropy and Customer Engagement, effective Aug. 29, 2016.
JNJ: 123.90 (-0.95), EXC: 36.57 (-0.21)
Global Pharmaceuticals Market Analytics Report 2016 Featuring Pfizer, Roche, Merk & Co., Sanofi, Gilead Sciences, Johnson & Johnson, Novartis, Abbvie, Amgen, GSK - Research and Markets
BusinessWire - Wed Aug 03, 8:13AM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Global Market Analytics Report 2016" report to their offering.
JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVS: 82.40 (-0.56)
Philogen Announces Collaboration With Johnson & Johnson Innovation
PR Newswire - Wed Aug 03, 7:00AM CDT
Philogen S.p.A. (a privately owned company) today announced that they have entered into a collaboration, option and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics. The agreement was facilitated by Johnson & Johnson Innovation.
JNJ: 123.90 (-0.95)
Medical benefits of dental floss unproven
By JEFF DONN - AP - Tue Aug 02, 1:13PM CDT
HOLMDEL, N.J. (AP) — It's one of the most universal recommendations in all of public health: Floss daily to prevent gum disease and cavities.
JNJ: 123.90 (-0.95)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.21 (+1.49), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), GERN: 2.78 (+0.06), CNAT: 2.37 (+0.04), AERI: 18.03 (+0.69), EXEL: 9.39 (+0.24)
Pfizer (PFE) Tops on Q2 Earnings, Revenues, Maintains View
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 8:08AM CDT
Pfizer (PFE) surpassed earnings and revenue estimates again in the second quarter.
JNJ: 123.90 (-0.95), PFE: 35.29 (-1.10), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Dermatological Drugs Market Forecast 2016-2026
PR Newswire Europe - Tue Aug 02, 8:03AM CDT
LONDON, August 2, 2016 /PRNewswire/ --
JNJ: 123.90 (-0.95)
Uptrend Call Working As Johnson & Johnson Stock Rises 22.4% (JNJ)
Comtex SmarTrend(R) - Tue Aug 02, 1:28AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on January 28th, 2016 at $102.45. In approximately 6 months, Johnson & Johnson has returned 22.41% as of today's recent price of $125.40.
JNJ: 123.90 (-0.95)
Stock Market News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Benchmarks closed mixed on Friday as upbeat tech earnings offset negative reports of energy firms and discouraging GDP data
KO: 43.64 (+0.11), AMZN: 754.64 (-5.94), FB: 122.51 (-0.58), LLTC: 59.22 (+0.05), XOM: 87.49 (+0.45), MS: 28.42 (+0.42), JNJ: 123.90 (-0.95), AA: 10.41 (+0.09), GS: 158.34 (+2.28), JPM: 64.66 (+1.01), MCD: 117.52 (-0.18), GOOGL: 798.92 (-1.20), MSFT: 56.97 (+0.39), CVX: 100.61 (+1.02), AAPL: 105.79 (+1.31)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)
Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:38AM CDT
With Geron (GERN) being a development stage company, investor focus will remain on imetelstat.
FATE: 2.06 (+0.01), JNJ: 123.90 (-0.95), GERN: 2.78 (+0.06), EXEL: 9.39 (+0.24)
Women with Ovarian Cancer from Baby Powder, Helped by Life Care Solution Group's Collaborative Effort
PR Newswire - Fri Jul 29, 11:46AM CDT
Greg Vigna, MD, JD, founder of Life Care Solutions Group and Jane Akre, founder of Mesh Medical Device News Desk today launch a collaborative effort to educate, empower, and assist catastrophically injured women with ovarian cancer, who were exposed to Johnson & Johnson Baby Powder containing Talc.
JNJ: 123.90 (-0.95)
AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 123.90 (-0.95), ABBV: 66.57 (-0.21), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
Merck (MRK) Updates Outlook Following Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
Merck (MRK) surpassed Q2 earnings expectations by a penny while revenues were in-line with estimates.
JNJ: 123.90 (-0.95), MRK: 57.65 (-0.68), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVLS: 4.83 (+0.02), CYTR: 0.61 (+0.04), CEMP: 22.20 (+2.04), ACUR: 1.88 (+0.04), NVS: 82.40 (-0.56)
McKesson (MCK) Beats on Q1 Earnings, Maintains Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:11AM CDT
McKesson Corporation (MCK) reported first-quarter fiscal 2017 (ended Jun 30, 2016) earnings of $3.50 per share, above the Zacks Consensus Estimate of $3.35.
ABC: 89.89 (+0.46), JNJ: 123.90 (-0.95), MCK: 195.14 (+1.61), BMY: 74.80 (-0.25)
2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21)
